目的：探讨高位泪囊鼻腔吻合术(DCR)联合RS泪道再通管治疗慢性泪囊炎的临床效果。方法：回顾性研究。选择2021年1月至2023年1月本院治疗的慢性泪囊炎患者110例110眼，根据治疗方法分为两组：对照组55眼采用高位DCR联合纳吸棉治疗； 观察组55眼采用高位DCR联合RS泪道再通管治疗。术后随访6 mo，比较两组患者临床疗效、生活质量和并发症发生情况。结果：术后6 mo，观察组解剖成功率(96.4%)高于对照组(83.6%)，总有效率(98.2%)高于对照组(78.2%)(均P<0.05)。术后6 mo两组简明健康状况调查表(SF-36)评分均较术前升高，且观察组评分高于对照组(均P<0.05)； 两组并发症发生率比较无差异(10.9% vs 20.0%，P>0.05)。结论：高位DCR联合RS泪道再通管治疗慢性泪囊炎患者安全、有效。

AIM: To explore the clinical effect of high dacryocystorhinostomy(DCR)combined with RS lacrimal duct recanalization on the treatment of chronic dacryocystitis.METHODS: Retrospective study. From January 2021 to January 2023, 110 patients(110 eyes)with chronic dacryocystitis treated in our hospital were collected and grouped according to the treatment method. The 55 eyes in the control group were treated with high DCR combined with suction cotton, and the 55 eyes in the monitored group were treated with high DCR combined with RS lacrimal duct recanalization. Follow-up for 6 mo, the clinical efficacy, quality of life, and complications were compared.RESULTS:At 6 mo after surgery, the monitored group had higher anatomical success rate than the control group(96.4% vs 83.6%), and had higher total effective rate than the control group(98.2% vs 78.2%; both P<0.05). At 6 mo after surgery, both groups had increased the Shot-Form Health Status Survey-36(SF-36)scores, with the monitored group having higher scores than the control group(all P<0.05); there was no statistical difference in complications between two groups(10.9% vs 20.0%, P>0.05).CONCLUSION:High DCR combined with RS lacrimal duct recanalization is safe and effective in treating patients with chronic dacryocystitis.